Dinaciclib in Treating Patients With Stage IV Melanoma

Inclusion Criteria

• •Biopsy-confirmed malignant melanoma
• •* Stage IV disease
• •* Cutaneous or mucosal origin
• •* Melanoma of unknown primary allowed
• •* No ocular melanoma
• •Measurable or non-measurable disease
• •No prior or concurrent brain metastases as confirmed by CT scan or MRI
• •Zubrod performance status 0-1
• •ANC ≥ 1,500/mm\^3
• •Platelet count ≥ 100,000/mm\^3
• •Hemoglobin ≥ 9 g/dL
• •Serum bilirubin ≤ 1.5 times upper limit of normal (ULN) (including patients with hepatic metastases)
• •SGOT or SGPT ≤ 2.5 times ULN (≤ 5 times ULN in the presence of hepatic metastases)
• •Serum creatinine ≤ 1.5 times ULN
• •Not pregnant or nursing
• •Fertile patients must use effective contraception
• •No other prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years
• •No prior therapy with a cyclin-dependent kinase inhibitor
• •At least 14 days since prior radiotherapy
• •At least 28 days since prior systemic chemotherapy
• •At least 28 days since prior adjuvant systemic therapy
• •At least 28 days since prior surgery
• •No more than 1 prior systemic therapy regimen (chemotherapy, biologic/immunotherapy, hormonal therapy, or a combination regimen) for stage IV melanoma and any side effects must have resolved to ≤ grade 1
• •Any number of prior adjuvant systemic therapy regimens allowed, including interferon alfa-2b, GM-CSF, chemotherapy, and chemobiotherapy
• •* Therapy for stage IV resected free-of-disease will be considered adjuvant therapy
• •Prior radiotherapy allowed provided any side effects have resolved to ≤ grade 1
• •Prior surgery (for both the primary and stage IV disease) allowed provided side effects have resolved to ≤ grade 1
• •No other concurrent or planned non-study treatment (including chemotherapy, hormonal therapy, biologic therapy, or radiotherapy)
• •No concurrent CYP3A4 inhibitors or inducers
• •No concurrent grapefruit or grapefruit juice